Apogee Therapeutics (APGE) Other Non-Current Liabilities (2022 - 2026)
Apogee Therapeutics (APGE) posted quarterly Other Non-Current Liabilities of $600000.0 for Q1 2026, down 71.43% quarter-over-quarter from $2.1 million in Q4 2025.
Apogee Therapeutics (APGE) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Other Non-Current Liabilities for 5 consecutive years, with $600000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $600000.0; the TTM figure through Mar 2026 stood at $600000.0 (changed N/A YoY), while the FY2025 annual figure was $2.1 million, up 2000.0% from the prior year.
- Other Non-Current Liabilities declined to $600000.0 in Q1 2026 per APGE's latest filing, from $2.1 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $8.0 million in Q4 2022 and bottomed at $100000.0 in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $3.0 million across 5 years, with a median of $2.1 million in 2025.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities plunged 98.08% — and 2025, when it jumped 2000.0%.
- Apogee Therapeutics' Other Non-Current Liabilities stood at $8.0 million in 2022, then plunged by 35.0% to $5.2 million in 2023, then slumped by 98.08% to $100000.0 in 2024, then surged by 2000.0% to $2.1 million in 2025, then sank by 71.43% to $600000.0 in 2026.
- Business Quant data shows APGE's Other Non-Current Liabilities at $600000.0 in Q1 2026, $2.1 million in Q4 2025, and $100000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Mar 31, 2026 | 600,000.00 |
| Dec 31, 2025 | 2.10 Mn |
| Jun 30, 2025 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 2.50 Mn |
| Dec 31, 2023 | 5.20 Mn |
| Sep 30, 2023 | 6.60 Mn |
| Jun 30, 2023 | 5.90 Mn |
| Dec 31, 2022 | 8.00 Mn |